Cargando…
Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease
Soluble amyloid-beta oligomers (Aβo) start to accumulate in the human brain one to two decades before any clinical symptoms of Alzheimer's disease (AD) and are implicated in synapse loss, one of the best predictors of memory decline that characterize the illness. Cognitive impairment in AD was...
Autores principales: | Hector, Audrey, Brouillette, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817907/ https://www.ncbi.nlm.nih.gov/pubmed/33488358 http://dx.doi.org/10.3389/fnmol.2020.600084 |
Ejemplares similares
-
Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease
por: Ferreira, Sergio T., et al.
Publicado: (2015) -
β-Amyloid oligomers in aging and Alzheimer’s disease
por: Zahs, Kathleen R., et al.
Publicado: (2013) -
Hippocampal injections of soluble amyloid-beta oligomers alter electroencephalographic activity during wake and slow-wave sleep in rats
por: Hector, Audrey, et al.
Publicado: (2023) -
The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer’s Disease
por: Viola, Kirsten L., et al.
Publicado: (2022) -
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
por: Krafft, Grant A., et al.
Publicado: (2022)